Regulus Therapeutics Inc. RGLS
We take great care to ensure that the data presented and summarized in this overview for Regulus Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RGLS
View all-
Federated Hermes, Inc. Pittsburgh, PA15.8MShares$129 Million0.06% of portfolio
-
Nea Management Company, LLC Timonium, MD6.47MShares$52.8 Million1.07% of portfolio
-
Octagon Capital Advisors LP New York, NY4.64MShares$37.8 Million2.7% of portfolio
-
Black Rock Inc. New York, NY3.97MShares$32.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.95MShares$32.2 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.26MShares$26.6 Million0.2% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.7MShares$22 Million1.28% of portfolio
-
Baker Bros. Advisors LP New York, NY2.69MShares$22 Million0.06% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.97MShares$16.1 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.3MShares$10.6 Million0.0% of portfolio
Latest Institutional Activity in RGLS
Top Purchases
Top Sells
About RGLS
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Transactions at RGLS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 25
2025
|
Stelios Papadopoulos |
SELL
Sale (or disposition) back to the issuer
|
Direct |
64,635
-100.0%
|
-
|
|
Jun 25
2025
|
Stelios Papadopoulos |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
976,253
-93.79%
|
-
|
|
Jun 25
2025
|
Pascale Witz |
SELL
Sale (or disposition) back to the issuer
|
Direct |
67,233
-100.0%
|
-
|
|
Jun 25
2025
|
William H Rastetter |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
57,292
-100.0%
|
-
|
|
Jun 25
2025
|
William H Rastetter |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
44,264
-43.59%
|
-
|
|
Jun 25
2025
|
Joseph P Hagan Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
571,558
-100.0%
|
-
|
|
Jun 25
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
83,125
-100.0%
|
-
|
|
Jun 25
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
60,796
-42.24%
|
-
|
|
Jun 25
2025
|
Preston Klassen President & Head of R & D |
SELL
Sale (or disposition) back to the issuer
|
Direct |
115,555
-100.0%
|
-
|
|
Jun 25
2025
|
Hugh Rosen |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,292
-100.0%
|
-
|
|
Jun 25
2025
|
Hugh Rosen |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,979
-10.86%
|
-
|
|
Jun 25
2025
|
Kathryn J Collier |
SELL
Sale (or disposition) back to the issuer
|
Direct |
75,565
-100.0%
|
-
|
|
Jun 25
2025
|
Alice Shih Hou Huang |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
57,292
-100.0%
|
-
|
|
Jun 25
2025
|
Alice Shih Hou Huang |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
27,377
-32.33%
|
-
|
|
Jun 25
2025
|
Alice Shih Hou Huang |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,292
-100.0%
|
-
|
|
Jun 25
2025
|
Alice Shih Hou Huang |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,208
-8.33%
|
-
|
|
Jun 25
2025
|
Jason Raleigh Nunn |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,500
-100.0%
|
-
|
|
Jun 25
2025
|
David Baltimore |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
57,292
-100.0%
|
-
|
|
Jun 25
2025
|
David Baltimore |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,208
-8.33%
|
-
|
|
Jun 25
2025
|
David Baltimore |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,292
-100.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.14M shares |
|---|---|
| Open market or private purchase | 85.6K shares |
| Exercise of conversion of derivative security | 6.33K shares |
| Sale (or disposition) back to the issuer | 1.52M shares |
|---|---|
| Disposition due to a tender of shares in a change of control transaction | 1.15M shares |
| Open market or private sale | 246K shares |